MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
Brain cancer awareness, grey ribbon on helping hand

MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing dealLarge…

Continue Reading MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ --…

Continue Reading MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China